Table 3.
Chemotherapy-induced change from baseline in p16INK4a mRNA expression to the follow-up visit by chemotherapy regimen and overall
| Regimen | Time point | No. | Mean log2 p16INK4a (95% CI) | Mean log2 change in p16INK4a (95% CI) | P a | Absolute change in p16INK4 (95% CI) | Change in age (95% CI), y |
|---|---|---|---|---|---|---|---|
| Overall | Baseline | 146 | 9.62 (9.46 to 9.77) | 0.47 (0.33 to 0.61) | <.001 | 1.39 (1.25 to 1.54) | 17 (12 to 22) |
| Follow-up visit | 146 | 10.09 (9.93 to 10.24) | |||||
| AC-T (Dose-dense doxorubicin and cyclophosphamide followed by paclitaxel) | Baseline | 53 | 9.53 (9.28 to 9.78) | 0.65 (0.46 to 0.84) | <.001 | 1.57 (1.38 to 1.79) | 23 (16 to 30) |
| Follow-up visit | 53 | 10.18 (9.93 to 10.43) | |||||
| AC-TC (Doxorubicin and cyclophosphamide followed by paclitaxel and carboplatin) | Baseline | 17 | 9.34 (8.87 to 9.82 | 0.74 (0.22 to 1.25) | .008 | 1.67 (1.16 to 2.38) | 26 (8 to 45) |
| Follow-up visit | 17 | 10.08 (9.65 to 10.52) | |||||
| TC (Docetaxel and cyclophosphamide ± anti-HER2 therapy) | Baseline | 51 | 9.79 (9.52 to 10.05) | 0.30 (0.04 to 0.57) | .03 | 1.23 (1.03 to 1.48) | 11 (1 to 20) |
| Follow-up visit | 51 | 10.09 (9.78 to 10.40) | |||||
| TCH (Docetaxel and carboplatin + anti-HER2 therapy) | Baseline | 25 | 9.64 (9.25 to 10.02) | 0.26 (−0.10 to 0.63) | .15 | 1.20 (1.00 to 1.55) | 9 (−4 to 23) |
| Follow-up visit | 25 | 9.90 (9.57 to 10.23) |
a
Paired t test and all 2-sided. CI = confidence interval.